BioVersys Announces 2026 Annual General Meeting of Shareholders

BioVersys AG has officially invited shareholders to its 2026 Annual General Meeting (AGM). Scheduled for April 30th in Basel, Switzerland, the meeting will address key agenda items including approval of the 2025 financial statements, discharge of board and committee members, and election of key positions. Dr. William Jenkins will not seek re-election, while Ms. Simona Skerjanec is nominated as a new board member due to her extensive pharmaceutical experience.

Shareholders must be registered by April 17, 2026, to participate in the AGM. All relevant documents, including the Annual Report and AGM invitation, are accessible on BioVersys's website. The company focuses on novel antibacterial products for infections caused by multi-drug resistant bacteria.